Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 40Lymphoma, Mantle-Cell 27Lymphoma 26Lymphoma, Follicular 25Lymphoma, Non-Hodgkin 23Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, B-Cell 14Lymphoma, B-Cell, Marginal Zone 13Burkitt Lymphoma 12Recurrence 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasms 8Waldenstrom Macroglobulinemia 6Leukemia, Hairy Cell 5Lymphoproliferative Disorders 4Leukemia 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3beta-Thalassemia 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm, Residual 2Lymphatic Diseases 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Leukemia, B-Cell 2Infections 2Hodgkin Disease 2Hematologic Neoplasms 2Epstein-Barr Virus Infections 2

Interventions

Etoposide 3daratumumab 2Vincristine 2Prednisone 2Doxorubicin 2Cyclophosphamide 2varlilumab 1prednylidene 1pomalidomide 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Specimen Handling 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Melphalan 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Dexamethasone 1Cytarabine 1Carmustine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmablastic Lymphoma × Rituximab × 90 days × Clear all
NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡